JP5616798B2 - ミトコンドリア由来の抗ガン化合物 - Google Patents

ミトコンドリア由来の抗ガン化合物 Download PDF

Info

Publication number
JP5616798B2
JP5616798B2 JP2010550000A JP2010550000A JP5616798B2 JP 5616798 B2 JP5616798 B2 JP 5616798B2 JP 2010550000 A JP2010550000 A JP 2010550000A JP 2010550000 A JP2010550000 A JP 2010550000A JP 5616798 B2 JP5616798 B2 JP 5616798B2
Authority
JP
Japan
Prior art keywords
cells
cancer
vitamin
tocopheryl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010550000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513437A (ja
JP2011513437A5 (enExample
Inventor
スティーブン・ジョン・ラルフ
イリ・ネウジル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008901261A external-priority patent/AU2008901261A0/en
Application filed by Individual filed Critical Individual
Publication of JP2011513437A publication Critical patent/JP2011513437A/ja
Publication of JP2011513437A5 publication Critical patent/JP2011513437A5/ja
Application granted granted Critical
Publication of JP5616798B2 publication Critical patent/JP5616798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2010550000A 2008-03-14 2009-03-16 ミトコンドリア由来の抗ガン化合物 Active JP5616798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008901261A AU2008901261A0 (en) 2008-03-14 Mitochondrially Delivered Anti-Cancer Compounds
AU2008901261 2008-03-14
PCT/AU2009/000312 WO2009111846A1 (en) 2008-03-14 2009-03-16 Mitochondrially delivered anti-cancer compounds

Publications (3)

Publication Number Publication Date
JP2011513437A JP2011513437A (ja) 2011-04-28
JP2011513437A5 JP2011513437A5 (enExample) 2013-05-02
JP5616798B2 true JP5616798B2 (ja) 2014-10-29

Family

ID=41064682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550000A Active JP5616798B2 (ja) 2008-03-14 2009-03-16 ミトコンドリア由来の抗ガン化合物

Country Status (7)

Country Link
US (2) US8598145B2 (enExample)
EP (1) EP2265623B1 (enExample)
JP (1) JP5616798B2 (enExample)
KR (1) KR101642157B1 (enExample)
CA (1) CA2734208C (enExample)
NZ (1) NZ602579A (enExample)
WO (1) WO2009111846A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012140660A1 (en) 2011-04-14 2012-10-18 Exalenz Bioscience Ltd. Methods for diagnosis, prognosis, monitoring and treatment of hepatocellular carcinoma
WO2012174287A1 (en) * 2011-06-15 2012-12-20 The Board Of Regents Of The University Of Texas System Luminescent nanoparticle compositions
HK1200459A1 (en) 2011-09-19 2015-08-07 Gencia Corporation Modified creatine compounds
WO2013181488A2 (en) * 2012-06-01 2013-12-05 The Ohio State University Research Foundation Inhibition of leukemic stem cells by pp2a activating agents
KR101764991B1 (ko) * 2013-04-24 2017-08-10 스마트 브레인 에스.알.오. 특히 높은 her2 단백질 농도를 갖는 신생물성 질환의 치료를 위한 타목시펜 유도체
US10953110B2 (en) 2014-04-25 2021-03-23 Board Of Regents, The University Of Texas System Dual emissive metal nanoparticles as ratiometric pH indicators
WO2016144637A1 (en) * 2015-03-06 2016-09-15 The Children's Hospital Of Philadelphia Tocopheryloxyacetate ester-based co-drug conjugates
CZ307146B6 (cs) * 2015-03-31 2018-02-07 Kkcg Se Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva
CA3004059A1 (en) 2015-11-04 2017-05-11 Prescient Pharma Llc Anti-aging compositions and methods for using same
KR102361131B1 (ko) * 2020-02-25 2022-02-10 경희대학교 산학협력단 항생제 내성 균주에 대해 항균활성을 갖는 항균용 조성물
CN116249557A (zh) * 2020-10-22 2023-06-09 白雁生物技术公司 包含抗癌药物的线粒体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) * 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
EP1254130B1 (en) 2000-02-11 2008-01-02 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
AUPQ605800A0 (en) * 2000-03-06 2000-03-30 Silverbrook Research Pty Ltd Printehead assembly
US20040241058A1 (en) * 2001-05-17 2004-12-02 Caro Colin G Production and processing plant with a rigid pipe portion curving in three dimensions
EP1664069B8 (en) 2003-08-22 2015-07-01 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
RU2007107359A (ru) 2004-07-28 2008-09-10 ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей
KR100556527B1 (ko) * 2004-11-04 2006-03-06 삼성전자주식회사 트렌치 소자 분리막 형성 방법 및 불휘발성 메모리 장치의제조 방법
US20080095834A1 (en) 2005-03-02 2008-04-24 Volkmar Weissig Mitochondriotropic Phospholipid Vesicles
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
AU2007295877B2 (en) 2006-09-15 2013-04-18 Cancure Limited Pro-oxidant anti-cancer compounds
JP4930026B2 (ja) * 2006-12-13 2012-05-09 富士ゼロックス株式会社 積層体、無端状ベルト、定着装置及び画像形成装置
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung

Also Published As

Publication number Publication date
CA2734208C (en) 2018-01-09
JP2011513437A (ja) 2011-04-28
EP2265623A1 (en) 2010-12-29
NZ602579A (en) 2013-12-20
AU2009225261A1 (en) 2009-09-17
WO2009111846A4 (en) 2009-11-05
KR101642157B1 (ko) 2016-07-22
WO2009111846A1 (en) 2009-09-17
USRE47300E1 (en) 2019-03-19
KR20100135803A (ko) 2010-12-27
CA2734208A1 (en) 2009-09-17
EP2265623B1 (en) 2016-07-13
EP2265623A4 (en) 2014-01-01
US20110105437A1 (en) 2011-05-05
US8598145B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
JP5616798B2 (ja) ミトコンドリア由来の抗ガン化合物
Lu et al. Mitochondria-targeted multifunctional nanoprodrugs by inhibiting metabolic reprogramming for combating cisplatin-resistant lung cancer
Zielonka et al. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications
Liu et al. Rational design of cancer-targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells
Liang et al. Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity
Li et al. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1
Jara et al. Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice
Xiang et al. Natural polyphenols-platinum nanocomplexes stimulate immune system for combination cancer therapy
US8410056B2 (en) Pro-oxidant anti-cancer compounds
Wang et al. Mitochondrial dysfunction is responsible for fatty acid synthase inhibition-induced apoptosis in breast cancer cells by PdpaMn
Chen et al. Improved stability and targeted cytotoxicity of epigallocatechin-3-gallate palmitate for anticancer therapy
Li et al. A trisulfide bond containing biodegradable polymer delivering pt (IV) prodrugs to deplete glutathione and donate H2S to boost chemotherapy and antitumor immunity
Kumar et al. Fisetin-loaded nanostructured lipid carriers: formulation and evaluations against advanced and metastatic melanoma
Liu et al. An EGCG-mediated self-assembled micellar complex acts as a bioactive drug carrier
Tunki et al. Serotonin-Functionalized Vit-E nanomicelles for targeting of Irinotecan to prostate cancer cells
Nethi et al. Polyanhydride copolymer-based niclosamide nanoparticles for inhibiting triple-negative breast cancer: metabolic responses and synergism with paclitaxel
AU2007217810B2 (en) Anticancer agents
Zhao et al. High-throughput screening-based design of multifunctional natural polyphenol nano-vesicles to accelerate diabetic wound healing
WO2015110040A1 (zh) 苯丁酸氮芥衍生物、制备方法及应用
Koufaki Vitamin E derivatives: a patent review (2010–2015)
AU2009225261B2 (en) Mitochondrially delivered anti-cancer compounds
Dey et al. Dual stimuli-responsive nanoprecursor of ascorbic acid and quinone methide disrupting redox homeostasis for cancer treatment
Dey et al. Poly-β-thioester-based cross-linked nanocarrier for cancer cell selectivity over normal cells and cellular apoptosis by triggered release of parthenolide, an anticancer drug
Miesel et al. Anticarcinogenic reactivity of copper-dischiffbases with superoxide dismutase-like activity
Dong et al. Vitamin E analogues as prototypic mitochondria-targeting anti-cancer agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140912

R150 Certificate of patent or registration of utility model

Ref document number: 5616798

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250